http://wiki.jackslab.org/index.php?action=history&feed=atom&title=Ch75_Dermatological_Pharmacology 2026-09-11T05:57:25Z 本wiki的该页面的版本历史 MediaWiki 1.19.2 http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17986&oldid=prev 2024-12-09T03:53:40Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:53的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>&lt;b style=color:#f80&gt;溴莫尼定 （0.33% 外用凝胶）&lt;/b&gt; 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;的每日一次治疗。亦可致暂时性血管收缩；患者&lt;b style=color:#e00&gt;反弹性红斑发生率不到 1% &lt;/b&gt;。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>&lt;b style=color:#f80&gt;溴莫尼定 （0.33% 外用凝胶）&lt;/b&gt; 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>&#160;</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;的每日一次治疗。亦可致暂时性血管收缩；患者&lt;b style=color:#e00&gt;反弹性红斑发生率不到 1% &lt;/b&gt;。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17985&oldid=prev 2024-12-09T03:53:24Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:53的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;的每日一次治疗。亦可致暂时性血管收缩；患者&lt;b style=color:#e00&gt;反弹性红斑发生率不到 1% &lt;/b&gt;。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div><ins class="diffchange diffchange-inline">&lt;b style=color:#f80&gt;</ins>溴莫尼定 （0.33% 外用凝胶）<ins class="diffchange diffchange-inline">&lt;/b&gt; </ins>是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;的每日一次治疗。亦可致暂时性血管收缩；患者&lt;b style=color:#e00&gt;反弹性红斑发生率不到 1% &lt;/b&gt;。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17984&oldid=prev 2024-12-09T03:51:45Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:51的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;<del class="diffchange diffchange-inline">的每日一次治疗。亦可致暂时性血管收缩；</del>&lt;b style=color:#e00&gt;<del class="diffchange diffchange-inline">患者反弹性红斑发生率不到 </del>1% &lt;/b&gt;。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;<ins class="diffchange diffchange-inline">的每日一次治疗。亦可致暂时性血管收缩；患者</ins>&lt;b style=color:#e00&gt;<ins class="diffchange diffchange-inline">反弹性红斑发生率不到 </ins>1% &lt;/b&gt;。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17983&oldid=prev 2024-12-09T03:51:34Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:51的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;的每日一次治疗。亦可致暂时性血管收缩；&lt;b style=color:#e00&gt;<del class="diffchange diffchange-inline">反弹性红斑患者发生率不到 </del>1% &lt;/b&gt;。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;的每日一次治疗。亦可致暂时性血管收缩；&lt;b style=color:#e00&gt;<ins class="diffchange diffchange-inline">患者反弹性红斑发生率不到 </ins>1% &lt;/b&gt;。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17982&oldid=prev 2024-12-09T03:51:21Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:51的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;<del class="diffchange diffchange-inline">的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 </del>1% <del class="diffchange diffchange-inline">的患者中。</del></div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;<ins class="diffchange diffchange-inline">的每日一次治疗。亦可致暂时性血管收缩；&lt;b style=color:#e00&gt;反弹性红斑患者发生率不到 </ins>1% <ins class="diffchange diffchange-inline">&lt;/b&gt;。</ins></div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17981&oldid=prev 2024-12-09T03:49:32Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:49的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 <del class="diffchange diffchange-inline">肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 </del>1% 的患者中。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉（1% 乳膏）&lt;/b&gt;&#160; 是一种 α1 <ins class="diffchange diffchange-inline">肾上腺素能激动剂，被批准用于成人&lt;b style=color:#0b0&gt;持续性酒渣鼻面部红斑&lt;/b&gt;的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 </ins>1% 的患者中。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17980&oldid=prev 2024-12-09T03:48:54Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:48的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;<del class="diffchange diffchange-inline">羟甲唑啉</del>&lt;/b&gt; <del class="diffchange diffchange-inline">（1% 乳膏） </del>是一种 α1 肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 1% 的患者中。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#0b0&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;<ins class="diffchange diffchange-inline">羟甲唑啉（1% 乳膏）</ins>&lt;/b&gt; <ins class="diffchange diffchange-inline"> </ins>是一种 α1 肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 1% 的患者中。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17979&oldid=prev 2024-12-09T03:48:35Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:48的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#<del class="diffchange diffchange-inline">f80</del>&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉&lt;/b&gt; （1% 乳膏） 是一种 α1 肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 1% 的患者中。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#<ins class="diffchange diffchange-inline">0b0</ins>&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉&lt;/b&gt; （1% 乳膏） 是一种 α1 肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 1% 的患者中。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17978&oldid=prev 2024-12-09T03:48:22Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:48的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#f80&gt;酒渣鼻持续性红斑&lt;/b&gt;<del class="diffchange diffchange-inline">。它会导致暂时性血管收缩，并且有反跳性红斑的报道。羟甲唑啉 </del>（1% 乳膏） 是一种 α1 肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 1% 的患者中。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#f80&gt;酒渣鼻持续性红斑&lt;/b&gt;<ins class="diffchange diffchange-inline">。它会导致暂时性血管收缩，并且有&lt;b style=color:#e00&gt;反跳性红斑&lt;/b&gt;的报道。&lt;b style=color:#f80&gt;羟甲唑啉&lt;/b&gt; </ins>（1% 乳膏） 是一种 α1 肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 1% 的患者中。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat http://wiki.jackslab.org/index.php?title=Ch75_Dermatological_Pharmacology&diff=17977&oldid=prev 2024-12-09T03:47:16Z

<p>‎<span dir="auto"><span class="autocomment">Brimonidine (溴莫尼定)</span></span></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr valign='top'> <td colspan='2' style="background-color: white; color:black;">←上一版本</td> <td colspan='2' style="background-color: white; color:black;">2024年12月9日 (一) 03:47的版本</td> </tr><tr><td colspan="2" class="diff-lineno">第152行：</td> <td colspan="2" class="diff-lineno">第152行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>=== Brimonidine (溴莫尼定) ===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>−</td><td style="background: #ffa; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 <del class="diffchange diffchange-inline">肾上腺素能激动剂，被批准用于每日一次治疗酒渣鼻持续性红斑。它会导致暂时性血管收缩，并且有反跳性红斑的报道。羟甲唑啉 </del>（1% 乳膏） 是一种 α1 肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 1% 的患者中。</div></td><td class='diff-marker'>+</td><td style="background: #cfc; color:black; font-size: smaller;"><div>溴莫尼定 （0.33% 外用凝胶） 是一种 α2 <ins class="diffchange diffchange-inline">肾上腺素能激动剂，被批准用于每日一次治疗&lt;b style=color:#f80&gt;酒渣鼻持续性红斑&lt;/b&gt;。它会导致暂时性血管收缩，并且有反跳性红斑的报道。羟甲唑啉 </ins>（1% 乳膏） 是一种 α1 肾上腺素能激动剂，被批准用于成人持续性酒渣鼻面部红斑的每日一次治疗。它还会导致暂时性血管收缩；反弹性红斑发生在不到 1% 的患者中。</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td><td class='diff-marker'>&#160;</td><td style="background: #eee; color:black; font-size: smaller;"><div>Brimonidine (0.33% topical gel) is an α2 adrenergic agonist approved for once-daily treatment of persistent erythema of rosacea. It causes temporary vasoconstriction, and rebound erythema has been reported. Oxymetazoline (1% cream) is an α1 adrenergic agonist approved for once-daily treatment of persistent facial erythema of rosacea in adults. It also causes temporary vasoconstriction; rebound erythema occurs in less than 1% of patients.</div></td></tr> </table>

Comcat